Clinical trial of ticagrelor in the treatment of acute myocardial infarction in patients with percutaneous coronary intervention after thrombolytic therapy
10.13699/j.cnki.1001-6821.2016.12.003
- VernacularTitle:替格瑞洛在急性心肌梗死溶栓后择期冠状动脉介入治疗的临床研究
- Author:
Bing-Hui SONG
1
;
Shu-Qing WANG
;
Shan-Shan JIA
;
Yong-Dong PAN
;
Hong CHEN
Author Information
1. 齐齐哈尔市第一医院 心内科
- Keywords:
ticagrelor;
clopidogrel;
acute myocardial infarction
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(12):1066-1068
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical efficacy and safety of ti-cagrelor and clopidogrelin the treatment of acute myocardial infarction in patients with percutaneous coronary intervention ( PCI ) after thrombolytic therapy.Methods A total of 130 ST -segment myocardial infarction (STEM) patients were randomly divided into control group (n=64) and treatment group ( n=66 ).The patients of control group were given clopi-dogrel 300 mg, maintenance dose 75 mg qd.The patients of treatment group were given ticagrelor 180 mg, maintenance dose 90 mg bid.All the patients of two groups received selective PCI successfully after 8-10 d treatment.The change of thrombolysis in myocardial infarction ( TIMI ) flow grades after operation , left ventricular ejection fraction ( LVEF) and left ventricular end -diastolic dimension ( LVEDD ) , the incidence of no-reflow/slow flow and adverse drug reactions after operation were compared between two groups.Results After operation, the TIMI flow grades and LVEF in treatment group were significantly higher than those in control group ( P<0.01 ).After operation , the LVEDD in treatment group was lower than that in control group , with significant difference ( P<0.01 ).The incidences of no -reflow/slow flow in treatment group and control group were 3.03%and 14.06%respectively , there was statistically significant difference in two groups ( P<0.05 ).Only some minor bleeding events happened in the two groups , there was no statistically significant difference in two groups after operation 6 months ( P>0.05 ).Conclusion Ticagrelor could support better clinical efficacy than clopidogre in selective PCI after thrombolytic therapy for acute myocardial infarction , which has a stronger anti -platelet aggregation function without increasing the incidence of bleeding events.
